Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.77 |
| ▸ | HTT | P42858 | 4/20 | 0.77 |
| ▸ | CTSB | P07858 | 3/20 | 0.77 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.77 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.77 |
| ▸ | CASP6 | P55212 | 2/20 | 0.77 |
| ▸ | NPC1 | O15118 | 1/20 | 0.77 |
| ▸ | BRD4 | O60885 | 1/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.77 |
| ▸ | DRD2 | P14416 | 1/20 | 0.77 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.77 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.77 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6538214 | 0.87 | MAPT (0.77) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| Nitroxoline SCHEMBL151248 | 0.87 | MAPT (1.00) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| Nitroxoline SCHEMBL29363027 | 0.87 | MAPT (1.00) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| Nitroxoline SCHEMBL28525149 | 0.85 | MAPT (0.97) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| Nitroxoline SCHEMBL28498884 | 0.85 | MAPT (0.97) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| Nitroxoline SCHEMBL17474134 | 0.85 | MAPT (0.97) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| Nitroxoline SCHEMBL28523453 | 0.85 | MAPT (0.97) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| Nitroxoline SCHEMBL16062144 | 0.85 | MAPT (0.97) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| Nitroxoline SCHEMBL28523276 | 0.85 | MAPT (0.97) | MAPTMEN1KMT2ALMNAALDH1A1 | |
| Nitroxoline SCHEMBL28995930 | 0.85 | MAPT (0.97) | MAPTMEN1KMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3590516-B1 | ANTITUMOR-EFFECT ENHANCER USING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025072673-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS IRE 1 INHIBITORS | AL22.02.01, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-11696917-B2 | Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-07-11 | — | — | US | disclosed |
| WO-2023031308-A1 | CCR2 INHIBITORS | ARTICA THERAPEUTICS B.V. (NL) | 2023-03-09 | — | — | WO | disclosed |
| CN-108349981-B | Novel pyrazolo [3, 4-d ] pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2021-03-30 | — | — | CN | disclosed |
| EP-3345907-B1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS OR SALTS THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2020-04-22 | — | — | EP | disclosed |
| US-20200061067-A1 | AGENT ENHANCING ANTITUMOR EFFECT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-02-27 | — | — | US | disclosed |
| US-10329300-B2 | Pyrazolo[3,4-d]pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-06-25 | — | — | US | disclosed |
| CN-108349981-A | Novel pyrazolo [3, 4-d ] pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2018-07-31 | — | — | CN | disclosed |
| US-20180201615-A1 | PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO. , LTD. (JP) | 2018-07-19 | — | — | US | disclosed |
| WO-2012110603-A1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | WO | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| EP-1590332-B1 | A PROCESS FOR THE SYNTHESIS OF BISBENZIMIDAZOLES AND THEIR DERIVATIVES. | UNIV DELHI (IN) | 2011-04-27 | — | — | EP | disclosed |
| US-5405843-A | Anticancer drug potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-04-11 | — | — | US | disclosed |
| EP-0363212-B1 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS (JP) | 1995-01-04 | — | — | EP | disclosed |
| US-5204348-A | Quinoline derivatives | MITSUI TOATSU CHEMICALS INC. (JP) | 1993-04-20 | — | — | US | disclosed |
| US-5112817-A | Anticancer Drug Potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1992-05-12 | — | — | US | disclosed |
| EP-0363212-A2 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | MAPT 4801/4885MEN1 2680/4885KMT2A 3298/4885 |
| US-11696917-B2 | Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound | ZYX, DPYD, ZFX | MAPT 4754/4885MEN1 1582/4885KMT2A 1785/4885 |
| US-20180201615-A1 | PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | ERBB2, JAK2, ERBB4 | MAPT 4038/4885MEN1 2827/4885KMT2A 1410/4885 |
| US-10329300-B2 | Pyrazolo[3,4-d]pyrimidine compound or salt thereof | ERBB2, JAK2, ERBB4 | MAPT 4038/4885MEN1 2827/4885KMT2A 1410/4885 |
| US-20200061067-A1 | AGENT ENHANCING ANTITUMOR EFFECT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND | ZYX, DPYD, ZFX | MAPT 4754/4885MEN1 1582/4885KMT2A 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.